These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 28939356)

  • 1. Self-assembly polymerization enhances the immunogenicity of influenza M2e peptide.
    Zou P; Li Y; Huang J; Wu F
    Microbes Infect; 2017 Dec; 19(12):648-654. PubMed ID: 28939356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection.
    Guo Y; He L; Song N; Li P; Sun S; Zhao G; Tai W; Jiang S; Du L; Zhou Y
    Microbes Infect; 2017 Dec; 19(12):641-647. PubMed ID: 28903071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influenza virus M2e with additional cysteine residues shows enhanced immunogenicity and protection against lethal virus challenge.
    Kaminaka K; Matsuda J; Nozaki C
    Viral Immunol; 2013 Aug; 26(4):291-5. PubMed ID: 23941675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An M2e-based synthetic peptide vaccine for influenza A virus confers heterosubtypic protection from lethal virus challenge.
    Ma JH; Yang FR; Yu H; Zhou YJ; Li GX; Huang M; Wen F; Tong G
    Virol J; 2013 Jul; 10():227. PubMed ID: 23834899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of immunity induced by M2e of influenza virus.
    Wu F; Huang JH; Yuan XY; Huang WS; Chen YH
    Vaccine; 2007 Dec; 25(52):8868-73. PubMed ID: 18061317
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
    Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
    J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin.
    Liu X; Guo J; Han S; Yao L; Chen A; Yang Q; Bo H; Xu P; Yin J; Zhang Z
    Vaccine; 2012 Oct; 30(46):6527-33. PubMed ID: 22959982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete protection against a H5N2 avian influenza virus by a DNA vaccine expressing a fusion protein of H1N1 HA and M2e.
    Park KS; Seo YB; Lee JY; Im SJ; Seo SH; Song MS; Choi YK; Sung YC
    Vaccine; 2011 Jul; 29(33):5481-7. PubMed ID: 21664216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin.
    Huleatt JW; Nakaar V; Desai P; Huang Y; Hewitt D; Jacobs A; Tang J; McDonald W; Song L; Evans RK; Umlauf S; Tussey L; Powell TJ
    Vaccine; 2008 Jan; 26(2):201-14. PubMed ID: 18063235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunogenicity of recombinant proteins including ectodomain of M2 influenza virus A].
    Stepanova LA; Kovaleva AA; Potapchuk MV; Korotkov AV; Kupriianov VV; Blokhina EA; Kotliarov RIu; Tsybalova LM
    Vopr Virusol; 2013; 58(3):21-5. PubMed ID: 24006628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant M2e outer membrane vesicle vaccines protect against lethal influenza A challenge in BALB/c mice.
    Rappazzo CG; Watkins HC; Guarino CM; Chau A; Lopez JL; DeLisa MP; Leifer CA; Whittaker GR; Putnam D
    Vaccine; 2016 Mar; 34(10):1252-8. PubMed ID: 26827663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel M2e-multiple antigenic peptide providing heterologous protection in mice.
    Wen F; Ma JH; Yu H; Yang FR; Huang M; Zhou YJ; Li ZJ; Wang XH; Li GX; Jiang YF; Tong W; Tong GZ
    J Vet Sci; 2016 Mar; 17(1):71-8. PubMed ID: 27051342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering of the PapMV vaccine platform with a shortened M2e peptide leads to an effective one dose influenza vaccine.
    Carignan D; Thérien A; Rioux G; Paquet G; Gagné ML; Bolduc M; Savard P; Leclerc D
    Vaccine; 2015 Dec; 33(51):7245-7253. PubMed ID: 26549362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin.
    Stepanova LA; Kotlyarov RY; Kovaleva AA; Potapchuk MV; Korotkov AV; Sergeeva MV; Kasianenko MA; Kuprianov VV; Ravin NV; Tsybalova LM; Skryabin KG; Kiselev OI
    PLoS One; 2015; 10(3):e0119520. PubMed ID: 25799221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential recombinant vaccine against influenza A virus based on M2e displayed on nodaviral capsid nanoparticles.
    Yong CY; Yeap SK; Ho KL; Omar AR; Tan WS
    Int J Nanomedicine; 2015; 10():2751-63. PubMed ID: 25897220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel M2e based flu vaccine formulation for dogs.
    Leclerc D; Rivest M; Babin C; López-Macias C; Savard P
    PLoS One; 2013; 8(10):e77084. PubMed ID: 24098576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine.
    Wu F; Yuan XY; Li J; Chen YH
    Vaccine; 2009 Jul; 27(32):4320-4. PubMed ID: 19410621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.